Skip to content
Wenlo
Sign in
← Markets

Gilead Sciences Inc.

Daniel Patrick O'Day (Chairman & CEO) sells GILD shares

4GILDFiled Nov 2, 2026, 7:14 PM ET· Period Oct 30, 2026

AI-generated summary

Daniel Patrick O'Day, Chairman & CEO, Director of Gilead Sciences Inc., exercised 15,881 options at an average price of $72.34 for $1,148,831.54. They also sold 30,881 shares of common stock at an average price of $172.57 for $5,329,177.65. Following these transactions, they directly held 551,683 shares. These trades were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Daniel Patrick O'Day · Chairman & CEO, Director

Rule 10b5-1 plan · adopted Feb 25, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Oct 30, 2026M · exercise or conversion of a derivativeFootnotes F1+15,881$72.34$1,148,831.54582,564Direct
Oct 30, 2026S · open-market saleFootnotes F1, F2−15,881$175.25$2,783,075.37566,683Direct
Nov 2, 2026S · open-market saleFootnotes F1, F3−1,600$167.40$267,839.84565,083Direct
Nov 2, 2026S · open-market saleFootnotes F1, F4−1,700$168.10$285,771.02563,383Direct
Nov 2, 2026S · open-market saleFootnotes F1, F5−1,904$169.27$322,296.36561,479Direct
Nov 2, 2026S · open-market saleFootnotes F1, F6−7,796$170.35$1,328,069.65553,683Direct
Nov 2, 2026S · open-market saleFootnotes F1, F7−2,000$171.06$342,125.40551,683Direct
Oct 30, 2026M · exercise or conversion of a derivativeNon-qualified Stock Option (Right to Buy)Footnotes F1, F8−15,881$0.00$0.00240,739Direct
Footnotes
  1. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
  2. F2 Sale prices for the transactions reported range from $175.05 to $175.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  3. F3 Sale prices for the transactions reported range from $166.69 to $167.66. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  4. F4 Sale prices for the transactions reported range from $167.72 to $168.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  5. F5 Sale prices for the transactions reported range from $168.78 to $169.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  6. F6 Sale prices for the transactions reported range from $169.83 to $170.82. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  7. F7 Sale prices for the transactions reported range from $170.83 to $171.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  8. F8 The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

More GILD filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.